Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase EARLY_PHASE1 1

Status

Recruiting 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1Alopecia 1

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Immunoconjugates × 1 year × Clear all
NCT07052760 2026-04-29

Imaging of Solid Tumors Using DLL3 SPECT

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT07474558 2026-03-16

SCARLET-ICE

Jules Bordet Institute

Phase 2 Not yet recruiting
102 enrolled

Alopecia

NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Ambrx, Inc.

Phase 2 Active not recruiting
72 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

MBrace Therapeutics

Phase 1/2 Recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

NCT06797999 2026-01-28

ADCElerate1

Adcendo ApS

Phase 1/2 Recruiting
270 enrolled
Sarcoma

Sarcoma

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Active not recruiting
44 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡